Adam J. Mead

A first-in-class CAR T-cell therapy targeting mutant calreticulin selectively depletes malignant stem cells in vivo and in fibrotic human organoids.

This study uses spatial transcriptomic analysis and machine learning to redefine the topology of human bone marrow in health and myeloproliferative neoplasms, revealing new insights into cellular heterogeneity and fibrosis.

This study uses CRISPR-Cas genome editing to selectively inactivate JAK2 V617F mutations in patient cells, showing that heterozygous cells are not oncogene addicted while homozygous cells are eradicated, suggesting genome editing as a potential treatment for MPNs.

This study shows that high cholesterol induces epigenetic changes in hematopoietic stem cells that persist after cholesterol reduction, leading to systemic immunometabolic dysfunction.

The paper identifies chromothripsis-induced amplification of DYRK1A in blast phase MPN as a driver of aggressive disease and a potential therapeutic target.

This paper introduces comBOs, a new human bone and lympho-myeloid bone marrow organoid model that includes multiple cell types and improves upon existing models for studying haematopoietic disorders.

This paper develops CRISPR-Lock, a CRISPR/dCas13 RNA blocker that disrupts miRNA-target interactions and rescues DM1 pathology by correcting splicing biomarkers and reducing nuclear foci.

MARVEL is an R package for single-cell alternative splicing analysis, benchmarked against existing tools and applied to iPSC differentiation studies.

This study identifies site- and stage-specific transitions in gene regulatory networks and lineage specification in human hematopoietic stem and progenitor cells across developmental stages.

This study introduces TARGET-seq, a method that simultaneously detects mutations and performs RNA-sequencing in single cells, revealing transcriptional and genetic tumor heterogeneity in myeloproliferative neoplasm cells.

This study shows foxd3 acts as a pioneer factor and then switches to a repressor in neural crest cells, dynamically remodeling chromatin structure to control stemness and cell fate.

Telomerecat estimates telomere length from whole-genome sequencing data without requiring prior knowledge of ploidy, showing good performance and detecting expected patterns in various data types.